Compare Charles River Laboratories Intl. Inc (CRL) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs KB Financial Group, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $303.81 (market cap $14.23B), while KB Financial Group, Inc. trades at $123.1 (market cap $42.62B). The key difference: KB Financial Group, Inc. is far larger — about 3× Charles River Laboratories Intl. Inc's market cap, and KB Financial Group, Inc. pays a 2.71% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and KB Financial Group, Inc. for 33 Days on average.
| CRL | KB | |
|---|---|---|
Market Cap | $14.23B | $42.62B |
Volume | 1,176,885 | 164,291 |
Sector | Health | Financials |
52-Week High | $310.77 | $132.88 |
52-Week Low | $149.93 | $77.50 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $17.06B | $215.53T |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
KB Financial Group trades at $122.78, down 1.56% today, with mixed technical signals showing neutral overall momentum. The company demonstrates strong fundamental performance with consistent earnings beats, growing revenue from $21.23T to $22.37T projected for 2026, and improving profit margins reaching 28.09%. Recent analyst coverage shows 33% buy ratings with positive momentum commentary from multiple financial outlets.
The outlook remains positive given KB's attractive valuation at 9.68 P/E and 0.94 P/B, coupled with sustained earnings growth. Key risks include market volatility and the company's significant investment outflows. Analyst consensus leans neutral with 67% hold ratings, suggesting cautious optimism for this value-oriented financial stock.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
